Scarica l'app Stockscreener
5.21
4.23%
-0.23
Pre-mercato:
5.05
-0.16
-3.07%
Precedente Chiudi:
$5.44
Aprire:
$5.36
Volume 24 ore:
1.65M
Relative Volume:
1.91
Capitalizzazione di mercato:
$102.21M
Reddito:
$146.07M
Utile/perdita netta:
$-196.04M
Rapporto P/E:
-0.3135
EPS:
-16.621
Flusso di cassa netto:
$-75.37M
1 W Prestazione:
-37.98%
1M Prestazione:
-48.36%
6M Prestazione:
-21.77%
1 anno Prestazione:
-6.96%
Intervallo 1D:
$5.095
$5.71
Intervallo di 1 settimana:
$5.095
$9.04
Portata 52W:
$3.51
$10.99
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Compare KPTI vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
5.21 | 102.21M | 146.07M | -196.04M | -75.37M | -16.62 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Iniziato | Rodman & Renshaw | Buy |
| 2026-02-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-10-13 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-07-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-07-11 | Ripresa | H.C. Wainwright | Buy |
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - TradingView
KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN
KPTI: Baird Lowers Price Target, Maintains Outperform Rating | K - GuruFocus
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $15.00 at Robert W. Baird - MarketBeat
HC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $8.00 - MarketBeat
H.C. Wainwright cuts Karyopharm stock price target on trial results By Investing.com - Investing.com Canada
HC Wainwright & Co. Lowers Price Target on Karyopharm Therapeuti - GuruFocus
Karyopharm raises $30M in private placement with RA Capital By Investing.com - Investing.com Australia
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark - Sahm
Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in MyelofibrosisSlideshow (NASDAQ:KPTI) 2026-03-25 - Seeking Alpha
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
Karyopharm’s myelofibrosis trial meets one of two primary goals By Investing.com - Investing.com India
KPTI Shares Fall Following Varied Results from Phase III Myelofibrosis Combination Study - Bitget
Leerink cuts Karyopharm stock price target on mixed trial data By Investing.com - Investing.com Canada
Why Is Karyopharm Therapeutics Stock Trading Lower Today?Karyopharm Therapeutics (NASDAQ:KPTI) - Benzinga
Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN
Karyopharm’s Phase 3 SENTRY Trial Shows Significant Spleen Reduction and Promising Overall Survival in Myelofibrosis with Selinexor Plus Ruxolitinib 1 - Minichart
Karyopharm phase III Sentry entry bucks rux in MF; to FDA next - BioWorld MedTech
Karyopharm, looking to jump-start Xpovio, reports mixed results in myelofibrosis - Fierce Pharma
Karyopharm research and financing developments - The Pharma Letter
Karyopharm shares rise 10% after mixed Phase 3 SENTRY trial results - MSN
KPTI Stock Faces Uncertainty Amid Financial Challenges - StocksToTrade
Karyopharm Therapeutics SENTRY Trial Hits Spleen Endpoint, Shows Early Survival Signal in Myelofibrosis - MarketBeat
RBC Capital maintains Outperform on Karyopharm stock after trial data By Investing.com - Investing.com Canada
RBC Capital maintains Outperform on Karyopharm stock after trial data - Investing.com
Karyopharm Therapeutics (KPTI) Stock Plunges 12.71% on $30M Financing Announcement - Blockonomi
Karyopharm (KPTI) Announces Positive Phase 3 Trial Results for S - GuruFocus
Karyopharm Therapeutics Inc. (KPTI) Stock: Drops 12.71% After $30M Private Placement Deal - CoinCentral
Karyopharm Shares Jump 10% Following Mixed Phase 3 Trial Outcomes on Myelofibrosis Treatment - StockInvest.us
Why Did KPTI Stock Tank 13% In Pre-Market Today? - Stocktwits
Karyopharm Therapeutics (KPTI) Secures $30M in Private Placement, Stock Soars - GuruFocus
KPTI: Selinexor plus ruxolitinib nearly doubled spleen response and improved survival in myelofibrosis - TradingView
Karyopharm Therapeutics Secures $30M Private Placement with RA Capital Management - citybiz
Karyopharm Announces Financing and Positive SENTRY Trial Results - TipRanks
Karyopharm (KPTI) Shares Surge After Positive Selinexor Trial Re - GuruFocus
Karyopharm Therapeutics Raises ~$30 Million in RA Capital Private Placement, $44 Million Warrant Upside - TradingView
SENTRY myelofibrosis data and $30M private placement reshape Karyopharm (NASDAQ: KPTI) - Stock Titan
Karyopharm posts trial win for Xpovio in myelofibrosis (KPTI) - Seeking Alpha
Karyopharm (KPTI) Announces $30M Private Placement Deal - GuruFocus
Karyopharm stock gains 10% on mixed Phase 3 trial data - Investing.com UK
Karyopharm stock gains 10% on mixed Phase 3 trial data By Investing.com - Investing.com South Africa
Karyopharm raises $30M in private placement with RA Capital - Investing.com
Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study - TradingView
Karyopharm Therapeutics announces topline results from Phase 3 SENTRY trial in myelofibrosis - Traders Union
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - Karyopharm
Karyopharm Announces $30 Million Private Placement with RA Capital - PR Newswire
New myelofibrosis drug combo shrank spleens in half of patients - Stock Titan
How The Selinexor Story Is Reframing Karyopharm Therapeutics (KPTI) And Its Growth Expectations - Yahoo Finance
Karyopharm Therapeutics Inc.: Fundamental Analysis and Financial Ratings | | US48576U2050 - marketscreener.com
Profit Recap: How sensitive is Karyopharm Therapeutics Inc to inflationShort Setup & Long-Term Safe Investment Plans - baoquankhu1.vn
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):